Emily P Zeitler, Mhs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4716792/publications.pdf

Version: 2024-02-01

471509 552781 44 719 17 26 citations h-index g-index papers 47 47 47 1220 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Risk of atrioesophageal fistula formation with contact force–sensing catheters. Heart Rhythm, 2017, 14, 1328-1333.	0.7	91
2	Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. Circulation, 2017, 136, 1387-1395.	1.6	58
3	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiology, 2021, 6, 1275.	6.1	49
4	Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy. Circulation, 2021, 143, 661-672.	1.6	47
5	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2017, 69, 2369-2379.	2.8	37
6	Cable externalization and electrical failure of the Riata family of implantable cardioverter-defibrillator leads: A systematic review and meta-analysis. Heart Rhythm, 2015, 12, 1233-1240.	0.7	35
7	Remote monitoring of cardiac implantable electronic devices (CIED). Trends in Cardiovascular Medicine, 2016, 26, 568-577.	4.9	35
8	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. American Heart Journal, 2017, 191, 21-29.	2.7	35
9	Exercise Training and Pacing Status in Patients With Heart Failure: Results From HF-ACTION. Journal of Cardiac Failure, 2015, 21, 60-67.	1.7	32
10	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	4.1	30
11	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	2.7	29
12	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	3.9	28
13	Outcomes 1 Year After Implantable Cardioverter–Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	25
14	The Food and Drug Administration and pragmatic clinical trials of marketed medical products. Clinical Trials, 2015, 12, 511-519.	1.6	20
15	Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. Europace, 2018, 20, 1621-1629.	1.7	20
16	Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. Heart Rhythm, 2020, 17, 447-454.	0.7	20
17	Predicting appropriate shocks in patients with heart failure: Patient level metaâ€analysis from SCDâ€HeFT and MADIT II. Journal of Cardiovascular Electrophysiology, 2017, 28, 1345-1351.	1.7	18
18	Arrhythmias in Female Patients: Incidence, Presentation and Management. Circulation Research, 2022, 130, 474-495.	4.5	17

#	Article	IF	CITATIONS
19	Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. Heart Rhythm, 2015, 12, 1558-1564.	0.7	12
20	Novel Devices in HeartÂFailure. JACC: Heart Failure, 2020, 8, 251-264.	4.1	11
21	Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. Journal of the American College of Cardiology, 2022, 79, 1050-1059.	2.8	9
22	Arrhythmia care in a value-based environment: Past, present, and future. Heart Rhythm, 2018, 15, e5-e15.	0.7	8
23	Physicians' perceptions of shared decisionâ€making for implantable cardioverterâ€defibrillators: Results of a physician survey. Journal of Cardiovascular Electrophysiology, 2019, 30, 2420-2426.	1.7	8
24	Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet). American Heart Journal, 2016, 171, 64-72.e2.	2.7	7
25	Defibrillator Lead Survival. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006649.	2.2	6
26	Women in procedural leadership roles in cardiology: The Women In Local Leadership (WILL) observational study. Heart Rhythm, 2022, 19, 623-629.	0.7	5
27	Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 763-771.	1.4	4
28	Evaluation of cardiovascular implantable electronic device leads post implant: ElectroPhysiology Predictable And SuStainable Implementation Of National Registries (EP PASSION). Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	1.3	4
29	Efficacy and safety of dronedarone across age and sex subgroups: a <i>post hoc</i> analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter. Europace, 2022, 24, 1754-1762.	1.7	3
30	Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDRâ€ICD Registry. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1897-1906.	1.2	3
31	Comparative effectiveness of cardiac resynchronization therapy in older patients with heart failure: Systematic review and meta-analysis. Journal of Cardiac Failure, 2022, 28, 443-452.	1.7	3
32	Funding of Studies Supporting IA Guideline Recommendations in Cardiovascular Medicine—A Systematic Review. Journal of the American Heart Association, 2021, 10, e019513.	3.7	2
33	A Company of Equals. Journal of the American College of Cardiology, 2015, 66, 589-591.	2.8	1
34	Regulation Without Representation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008561.	4.8	1
35	Pre-Diabetes and Stroke in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 77, 885-887.	2.8	1
36	Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With HeartÂFailure. JACC: Heart Failure, 2022, 10, 147-157.	4.1	1

#	Article	IF	CITATIONS
37	Leadless pacemaker implantation complications and the denominator problem. Journal of Cardiovascular Electrophysiology, 2022, 33, 160-163.	1.7	1
38	The J wave patterns and risk of sudden cardiac death in patients with coronary artery disease. Journal of Electrocardiology, 2013, 46, 446-450.	0.9	O
39	Primary prevention implantable cardioverter defibrillators in women: More questions than answers. American Heart Journal, 2015, 170, 197-199.	2.7	0
40	Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women― Circulation: Heart Failure, 2016, 9, .	3.9	0
41	Fidelis Replacement. JACC: Clinical Electrophysiology, 2019, 5, 1068-1070.	3.2	O
42	Abstract 9920: Outcomes Associated With Lead Abandonment versus Lead Extraction Strategies for Revision of Sterile Leads: An NCDR® Analysis. Circulation, 2015, 132, .	1.6	0
43	A difficult entanglement: Guidewire entrapment within the submitral apparatus following transseptal access. HeartRhythm Case Reports, 2020, 6, 819-822.	0.4	O
44	Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic HeartÂFailure. JACC: Heart Failure, 2022, 10, 172-174.	4.1	0